Medicinal applications of cannabis/cannabinoids

Area of Science:

• Pharmacology and Therapeutics
• Neurology
• Evidence-Based Medicine

Background:

• Regulatory approval of purified cannabidiol (Epidiolex) for drug-resistant epilepsy establishes a precedent for prescription cannabinoids.
• Cannabis-based products are frequently anecdotally recommended for pain and insomnia management.
• The scientific evidence supporting these common uses remains underdeveloped.

Purpose of the Study:

• To critically review the evidence for the efficacy of cannabinoids in treating pain and insomnia.
• To compare the strength of evidence for pain and insomnia with that for epilepsy.
• To inform clinical prescribing practices regarding cannabis-based products.

Main Methods:

• Literature review and critical appraisal of existing clinical trials.
• Assessment of methodological quality and statistical significance of studies.
• Comparison of evidence levels across different indications.

Main Results:

• Evidence for purified cannabidiol efficacy in pain management is poorly developed, with low-quality trials suggesting minimal benefit.
• The scientific basis for using cannabinoids to treat insomnia is notably scant.
• The current evidence level is insufficient to support widespread prescribing for pain or insomnia.

Conclusions:

• The established efficacy for epilepsy does not translate to other conditions like pain and insomnia.
• Ongoing research and critical evaluation are essential to avoid overstating benefits based on anecdotal reports.
• Prescribing decisions for cannabis-based products should be guided by robust scientific evidence, not anecdotal claims.